➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson

Last Updated: April 17, 2021

DrugPatentWatch Database Preview

NYMALIZE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Nymalize patents expire, and when can generic versions of Nymalize launch?

Nymalize is a drug marketed by Arbor Pharms Llc and is included in one NDA. There are four patents protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in NYMALIZE is nimodipine. There are eight drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the nimodipine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nymalize

A generic version of NYMALIZE was approved as nimodipine by HERITAGE PHARMS INC on May 2nd, 2007.

  Start Trial

Summary for NYMALIZE
International Patents:2
US Patents:4
Suppliers / Packagers: 1
Bulk Api Vendors: 106
Clinical Trials: 1
Patent Applications: 3,908
Formulation / Manufacturing:see details
Drug Prices: Drug price information for NYMALIZE
What excipients (inactive ingredients) are in NYMALIZE?NYMALIZE excipients list
DailyMed Link:NYMALIZE at DailyMed
Drug patent expirations by year for NYMALIZE
Drug Prices for NYMALIZE

See drug prices for NYMALIZE

Recent Clinical Trials for NYMALIZE

Identify potential brand extensions & 505(b)(2) entrants

Johns Hopkins UniversityEarly Phase 1

See all NYMALIZE clinical trials

Pharmacology for NYMALIZE

US Patents and Regulatory Information for NYMALIZE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Arbor Pharms Llc NYMALIZE nimodipine SOLUTION;ORAL 203340-001 May 10, 2013 DISCN Yes No   Start Trial   Start Trial   Start Trial
Arbor Pharms Llc NYMALIZE nimodipine SOLUTION;ORAL 203340-002 Apr 8, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Arbor Pharms Llc NYMALIZE nimodipine SOLUTION;ORAL 203340-002 Apr 8, 2020 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.